Endoscopic examination plays a crucial role in the secondary prevention of gastric cancer. However, its effectiveness is often limited by the subjective nature of assessment and the risk of missing neoplastic lesions. The use of deep learning (DL) and machine learning (ML) models allows for a significant improvement in the quality of endoscopic diagnosis of early gastric cancer. Real-time systems increase the sensitivity of the examination and reduce skill-based differences between endoscopists. They also enable precise assessment of tumor invasion depth, which is essential for qualifying patients for minimally invasive treatment. Explainable artificial intelligence (XAI) methods and ML algorithms are gaining increasing importance as they enhance the transparency of the diagnostic process. Despite promising data, the full implementation of AI systems in endoscopy faces challenges such as susceptibility to imaging artifacts, the risk of model overfitting, and regulatory hurdles. A key issue remains the development of representative, multicenter training image databases and the conduct of prospective clinical trials, which may revolutionize standards of care. The aim of this article is to discuss the role of AI-assisted gastroscopy in the prevention of early gastric cancer, with particular emphasis on its potential in population-based screening programs. The paper presents current clinical data and analyzes the benefits and challenges associated with implementing these technologies into routine clinical practice.
19 December 2025 in International Journal of Innovative Technologies in Social Science
Research objectives: Regular physical activity is widely recognized as a key component of a healthy lifestyle. While moderate effort brings numerous benefits, engaging in extreme physical activity introduces new challenges and risks. Intense exercise, despite its undeniable health benefits, can lead to unpredictable changes in the body. This paper identifies the possible adaptive changes of the cardiovascular system and the risk of developing overtraining syndrome as a result of long-term practice of intense exercise. Methods and key findings: Two medical textbooks, thirty-eight scientific articles published between 2010 and 2024, and one article from 2005 were reviewed, with findings indicating that regular high-intensity training can lead to myocardial hypertrophy, reduced resting heart rate, and a smaller increase in heart rate in response to submaximal effort. An increased risk of arrhythmias and myocardial fibrosis has been observed in competitive athletes. Prolonged excessive exercise can result in overtraining syndrome, which may present as persistent fatigue, muscle and joint discomfort, and mood disturbances, among other symptoms. Conclusions: The paper emphasizes the need to individualize training programs and proves the validity of regular monitoring of athletes' health. It also highlights the necessity for further research into overtraining syndrome and the adaptation of the cardiovascular system to intense exercise. Particular attention was paid to the diagnostic difficulties associated with overtraining syndrome due to the subjectivity of symptoms and the limited number of clinical studies. The significance of an interdisciplinary approach in understanding the body's adaptation to overload was emphasized, considering physiological, biochemical, and psychological factors.
29 December 2025 in International Journal of Innovative Technologies in Social Science
The growing number of oncological patients worldwide pushes the need to research new possibilities in cancer treatment. Cancer cells use various mechanisms to avoid destruction. One of them is the PD-1/PD-L1 pathway which is used by neoplasm cells to inhibit immune response from T-cells. Pembrolizumab, a monoclonal antibody, is targeted against PD-1 receptors, therefore enhances anti-cancer T-cell activity by disabling PD-1/PD-L1 interaction. This study summarizes the current state of knowledge on clinical usefulness and efficiency of pembrolizumab monotherapy, therapy combined with chemotherapy and perioperative use in melanoma, non-small cell lung cancer, pleural mesothelioma, classic Hodgkin lymphoma, urothelial cancer, head and neck squamous cell carcinoma, renal cell carcinoma, high-level microsatellite instability (MSI-H) or demismatch repair deficiency (dMMR) neoplasm, esophageal cancer, triple negative breast cancer, endometrial cancer, cervical cancer, adenocarcinoma of the stomach or gastroesophageal junction and bile duct cancer. Patients who received pembrolizumab during clinical trials had longer median overall survival and progression free survival rates than patients in placebo groups. Higher expression levels of PD-L1 on tumor cells correlated with greater clinical response, however pembrolizumab therapy was also beneficial in patients with lower expression levels.
23 June 2026 in International Journal of Innovative Technologies in Social Science
Background: Vascular cognitive impairment (VCI) is a major contributor to age-associated cognitive decline, both independently and as a contributor to mixed dementia syndromes. Despite many years of research, an approved therapy has not yet been identified. Methods: We reviewed preventive and therapeutic strategies tested in VCI and meta-analyzed efficacy data for eligible interventions to assess whether previously tested treatments warranted reconsideration. Results: VCI clinical trials exhibited substantial heterogeneity. Few interventions were reproducibly tested in adequately sized and designed studies. Nonetheless, some interventions showed modest effects on global cognition and functional outcomes. Conclusion: Early and effective management of cerebrovascular risk factors, particularly beginning in midlife, plays a crucial role in lowering the likelihood of developing neurodegenerative conditions such a vascular cognitive impairment and other related dementias. Ginkgo biloba extracts and acetylcholinesterase inhibitors have shown the greatest cognitive and functional benefits, though their clinical significance remains uncertain, and certainty of evidence is overall low.
25 August 2026 in International Journal of Innovative Technologies in Social Science
Objective: The aim of this review was to evaluate the clinical efficacy, optimization of dosing regimens, safety profile, and socioeconomic aspects of natalizumab (NTZ) use in the treatment of multiple sclerosis (MS), with a additional focus on pregnant and pediatric populations. Methodology: A systematic review of the PubMed database was conducted, identifying 220 records. Thirty-two publications meeting the criteria regarding the mechanism of action, efficacy, adverse event profile, and comparison with other disease-modifying therapies (DMTs) were included in the final analysis. Results: The analysis demonstrated that the extended interval dosing (EID, every 6 weeks) regimen maintains clinical and radiological efficacy comparable to the standard interval dosing (SID, every 4 weeks), while significantly reducing the risk of progressive multifocal leukoencephalopathy (PML) by 88–94%. It was recognized that natalizumab is safer than other DMTs, such as ocrelizumab, without compromising efficacy. In the pediatric population, NTZ showed the highest efficacy in reducing relapse rates compared to fingolimod and injectable therapies. In pregnant women, continuing treatment until the 34th week prevents postpartum rebound relapses and improves EDSS scores, showing no teratogenic effects. Economically, the subcutaneous form of NTZ and the use of EID generate significant direct and societal cost savings. Conclusions: Natalizumab remains a highly effective and cost-efficient therapeutic option for the treatment of relapsing-remitting MS. Personalization of treatment through the EID regimen and the subcutaneous formulation allows for an improved safety profile and patient quality of life, while simultaneously reducing the systemic burden on healthcare.
6 January 2026 in International Journal of Innovative Technologies in Social Science
Running places high metabolic, neuromuscular and physiological demands on athletes, stimulating interest in nutritional supplements that may enhance performance and delay fatigue. Various ergogenic aids - including caffeine, creatine, β-alanine and beetroot-derived nitrates, have been investigated, yet their relative effectiveness across different running modalities remains unclear. A systematic search of PubMed (2010–2025) using the terms “supplementation” and “running” identified 234 records. After screening titles, abstracts and full texts according to predefined criteria, 26 studies evaluating single-ingredient supplements and reporting running-specific outcomes were included. A narrative synthesis was conducted due to heterogeneity in study designs and performance tests. Caffeine consistently improved running performance across sprint, repeated and endurance efforts by extending time to exhaustion, enhancing acceleration and increasing metabolic activation without elevating physiological strain. Creatine improved mean power, maintained running speed and reduced fatigue during short and repeated high-intensity efforts, with limited effects in endurance running. β-alanine increased muscle carnosine content and enhanced tolerance to high-intensity or fatigue-inducing exercise, while producing modest improvements during submaximal workloads. Beetroot-derived nitrates improved performance primarily in short, intense and intermittent running, especially in moderately trained athletes, whereas betalains supported recovery through antioxidant and anti-inflammatory mechanisms. Caffeine, creatine, β-alanine and beetroot-derived supplements all exert ergogenic effects, but their benefits are exercise-specific. Matching the supplement to the running demands and athlete characteristics is essential for maximizing performance outcomes.